Molecular Subtype Specific Therapy In High Grade Serous Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$832,254.00
Summary
High grade serous ovarian cancer (HGSC) is the most common type of ovarian cancer, accounting for about two thirds of all deaths from the disease.Several years ago we identified distinct subtypes of HGSC (C1, C2, C4, C5) based on patterns of gene activity. We found that women with the C5 subtype generally had poor survival, and we mapped genes that were specifically active in C5 tumours. In this application we aim to develop therapies that are specifically targeted to the C5 HGSC.
The Fellowship would support Professor Bowtell, one of the world’s leading ovarian cancer researchers. His work focuses on clinical problems of chemotherapy resistance and the development of new therapeutic approaches. His studies are underpinned by the Australian Ovarian Cancer Study (AOCS), one of the world’s most sophisticated clinical cohort studies of ovarian cancer, with over 3000 Australian women enrolled.
A Single Nucleotide Resolution Map Of A Cancer Associated Neochromosome
Funder
National Health and Medical Research Council
Funding Amount
$567,350.00
Summary
Neochromosomes (NCs) are large chromosomes which are not usually found in a normal cell. Well differentiated liposarcoma (WDLPS) is a tumour which is almost universally associated with the presence of NCs. We are using the approach of purifying the NC from a series of WDLPS cell lines, and using new techniques to derive the DNA sequence of the neochromosome. We will use this information to identify the genetic factors on the NC which are involved in the initiation or progression of WDLPS.
Defining The Role Of The PSA-related Kallikrein Serine Proteases In Hormone Dependent Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$880,454.00
Summary
Kallikreins are a family of 15 proteins, related to the prostate cancer biomarker PSA, that have potential as biomarkers for hormone dependent cancers such as prostate and ovarian cancer. Prof Judith Clements and her team discovered that kallikreins induce resistance to chemotherapy in ovarian cancer and are found in prostate cancer bone disease. Her research will determine the underlying mechanisms of kallikrein action and their potential as new biomarkers or treatment targets for these disease ....Kallikreins are a family of 15 proteins, related to the prostate cancer biomarker PSA, that have potential as biomarkers for hormone dependent cancers such as prostate and ovarian cancer. Prof Judith Clements and her team discovered that kallikreins induce resistance to chemotherapy in ovarian cancer and are found in prostate cancer bone disease. Her research will determine the underlying mechanisms of kallikrein action and their potential as new biomarkers or treatment targets for these diseases.Read moreRead less
Global Characterization Of The Src-regulated Kinome
Funder
National Health and Medical Research Council
Funding Amount
$591,334.00
Summary
This proposal aims to use new cutting-edge techniques to globally characterize the impact of a particular cancer-causing gene, or oncogene, on the expression and function of an important family of regulatory proteins, termed kinases, in cancer cells. This will identify proteins critical for cancer cell growth and survival that represent potential targets for therapy.
Identification Of Novel Treatment Strategies For Human Cancers Through Integrative Phosphoproteomics And Kinomics.
Funder
National Health and Medical Research Council
Funding Amount
$763,409.00
Summary
This proposal aims to use new cutting-edge techniques to characterize, at a global level, changes in growth regulatory signals in cancer cells. This will identify proteins critical for cancer growth that represent potential targets for therapy. In addition it will highlight ways to select the most effective treatments for individual patients. The ultimate outcome of this work will be improved treatment strategies for cancer patients, and hence reduced morbidity and mortality.
It is seldom the initial cancer that kills the patient; most deaths are due to its metastatic spread throughout the body. Survival after the onset of a brain metastasis is dismal. Current understanding of cancer spread to the brain is poor and yet an ability to inhibit this process would save thousands of lives each year. Using rare tissue resources and cutting-edge technologies, this project will elucidate molecular features of brain metastases that can be exploited to generate new treatments.